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Background: Psoriasis is associated with a variety of psychological diﬃculties, including poor self-esteem, sexual dysfunction, anxiety,
depression, and suicidal ideation.
Objectives: The aim of this study was to obtain further data on the extent of depression among psoriatic patients, the eﬀectiveness of
adalimumab treatment on the depression symptoms associated with psoriasis and to explore the association between improvement in
depression symptoms and improvement in Psoriasis Area and Severity Index.
Methods: The eﬀects of adalimumab (40 mg every other week) on ZDS score and PASI at week 24 were assessed. Relationships
between ZDS and PASI were assessed. Changes in ZDS score were compared for patients with and without a 75% or greater reduction
in baseline PASI score. An improvement of 6 points or more in the Zung depression scale was considered a clinically meaningful
improvement.
Results: Forty ﬁve Patients with moderate to severe psoriasis were assessed for depression symptoms at baseline and week 24 using
the Zung Self-rating Depression Scale (ZDS). At month 6 after starting adalimumab, 80% of enrolled patients achieved 75% improve-
ment in their PASI score (PASI75) at month 6 of adalimumab therapy and 97.8% achieved a meaningful improvement of Zung depres-
sion score (more than 6 points decline in the Zung depression score). Age at time of assessment signiﬁcantly predicted depression
(p = 0*030), with the younger age predicting a higher depression score (standard co-eﬃcient -.451). Achieving PASI 75 could signiﬁcantly
predict improvement in depression (p = 0.002, standard coeﬃcient-.746).http://dx.doi.org/10.1016/j.jdds.2014.03.005
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tions in depression symptoms were signiﬁcantly correlated with reductions in psoriasis severity.
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Psoriasis is a common chronic condition that aﬀects 1–
3% of the general population and estimates suggest that
0.4–2.3% of the adult population have psoriasis but remain
undiagnosed (Kurd and Gelfand, 2003).
Psoriasis is associated with a variety of psychological
diﬃculties, including poor self-esteem, sexual dysfunction,
anxiety, depression, and suicidal ideation. Psoriasis is asso-
ciated with substantial impairment of health-related quality
of life (HRQOL), negatively impacting psychological,
vocational, social, and physical functioning (Skevington
et al., 2006). The psychiatric morbidity in psoriasis may
be primary or secondary to the impact of the disease upon
the patient’s quality of life. The psychological and psychi-
atric morbidity in psoriasis is often a more important indi-
cator of the disability experienced by the patient than the
dermatologic aspects of the disorder (Kirkby et al., 2001).
Psoriasis-related stress has been associated with greater
psychiatric morbidity (Fortune et al., 1997). A wide range
of psychological characteristics have been reported in var-
ious cross sectional surveys including high depression/anx-
iety scores, obsessionality, and diﬃculties with verbal
expression of emotions, especially anger, social stigmatiza-
tion, high stress levels, physical limitations, depression,
employment problems and other psychosocial comorbidi-
ties experienced by patients with psoriasis are not always
proportional to, or predicted by, other measurements of
disease severity, such as body surface area involvement or
plaque severity (Gupta et al., 1987).
Relatively high rates of depression are reported in
patients with psoriasis (Bougue´on and Misery, 2008; Van
Voorhees and Fried, 2009). Studies found notably higher
degrees of depression in patients with psoriasis than con-
trols (Hardy and Cotterill, 1982). In another study, 35 of
76 (46%) study patients claimed that they were “often” or
“always” depressed (Devrimci-Ozguven et al., 2000)
because of their condition. In the Akay et al. (2002) study
depression rate was 58% in the patients with psoriasis and
53% in the patients with lichen planus, while it was 20% in
the control group.
Tumor necrosis factor (TNF), a proinﬂammatory cyto-
kine, has been implicated in the pathogenesis of both pso-
riasis and depression (Chodorowska, 1998; Haack et al.,
1999; Gupta and Gupta, 2003). Patients with psoriasis have
elevated concentrations of TNF in skin and serum samples,
and a direct correlation exists between TNF concentrations
and psoriasis symptoms as measured by Psoriasis Area and
Severity Index (PASI) scores Mussi et al., 1997.Signiﬁcantly elevated concentrations of TNF have been
observed in the plasma of patients with acute depression
and in patients with major depression who are resistant
to therapy for depression. These ﬁndings suggest that inhi-
bition of inﬂammatory cytokines in patients with depres-
sion may improve depression symptoms (Himmerich
et al., 2008).
Adalimumab is a fully human monoclonal IgG1 anti-
body against TNF that has demonstrated eﬃcacy and
safety in the treatment of moderate to severe psoriasis. In
addition to reducing the physical symptoms of psoriasis,
adalimumab has been shown to improve dermatology-spe-
ciﬁc and general mental and physical HRQOL to levels
comparable with that of the general population (Revicki
et al., 2008).
2. Study objective(s)
The objective of this study was to assess changes in the
depression symptoms in patients with psoriasis before and
after the addition of adalimumab therapy using Zung
Depression Scale Zung (1970), also to assess the correlation
between improvement in depression symptoms and other
factors such as age, gender, disease duration, BMI &
improvement in PASI in patients are included in the study.
3. Methods and patients
This was a post-registration, observational, surveillance,
prospective, non-comparative study that was conducted in
Saudi Arabia with a total of 45 patients. The study proto-
col was restricted to patients fulﬁlling the following search
criteria: (i) patient’s age >18 years, (ii) with moderate to
severe chronic plaque psoriasis, (iii) with a degree of
depression, as measured by Zung Self-rating Depression
Scale (ZDS) (50 points or more) and (iv) with no contrain-
dications or objections to receive adalimumab treatment.
Patients on anti-depressant therapy for a period of less
than 6 months at the time of inclusion in the study were
excluded.
The study was approved by local Clinical Research Eth-
ics Committees and was carried out in accordance with the
principles contained in the Declaration of Helsinki. Writ-
ten informed consent was obtained from every subject
prior to study entry.
Patients received treatment with adalimumab according
to the prescribed drug information detailed in the summary
of product characteristics and physicians’ clinical practice.
The initial dose was 40 mg every other week, any changes
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recorded in the study follow up sheets. Each patient was
observed for a period of maximum 6 months, if the patient
withdrew within the period of 6 months of follow-up then
the results of the last follow-up visit would be used for
result analysis.
Demographic and baseline clinical data were collected at
patient enrollment, including PASI, ZDS and the use of
concomitant medications. Before treatment, a chest X-ray
and a tuberculin skin test (TST) with protein-puriﬁed
derivative were performed to rule out latent tuberculosis.
Follow-up data (physical examination, vital signs and lab-
oratory tests, disease activity, observed AEs, and concom-
itant used drugs) were collected in every follow up visit.
Treatment eﬀectiveness in skin manifestations was eval-
uated in terms of PASI, ranging from 0 to 72. PASI 75 was
calculated based on patients showing P75% improvement
in their PASI scores. Depression status was evaluated in
terms of ZDS, with a score between 25 and 49 points inter-
preted as no depression, mild depression is between 50 and
59 points, moderate depression is between 60 and 69 points
and severe depression isP70 points. An improvement of 6
points or more in the Zung depression scale was considered
a clinically meaningful improvement.Table 1
Patients on concomitant medications.*
Concomitant medications N (%)
No 16 (35.6)
Steroids 14 (31.1)
Emollients 25 (55.6)
Keratolytics 7 (15.6)
Phototherapy 4 (8.9)
Methotrexate 2 (4.4)
Calcipotriol 1 (2.2)
* 20 Patients were on more than one
concomitant medication.4. Statistical analysis
This is an observational study conducted during the per-
iod from September 2012 to April 2013 in three centers.
Continuous variables were described using the mean,
median and standard deviation, whereas categorical vari-
ables were described by their absolute and relative frequen-
cies. Safety was evaluated regarding occurrence of AEs and
changes in laboratory values in all patients were included in
the study; this sample was also used for the description of
baseline characteristics. Eﬃcacy analysis was performed on
the intent-to-treat population, deﬁned as all patients
included in the study, using a visit-wise approach. For
the primary eﬃcacy variables, missing ﬁnal data were
imputed using last observation carried forward (LOCF).
All tests were 2-sided and the 0.05 level was used as the
cut oﬀ value for statistical signiﬁcance and the following
statistical measures were used. All analyses were performed
using the SPSS statistical software, version 15.0 (SPSS Inc.,
Chicago, IL, USA).Figure 1. PASI and Zung depression scores – response to adalimumab
therapy.5. Results
Of the 51 patients with a diagnosis of moderate-to-
severe plaque psoriasis screened for DORADO-Ps, 45
(88%) gave consent to participate in the study. At month
6, 100% of the enrolled patients completed the study. Over-
all, 44.4% of patients enrolled were females while 55.6%
were males, and 97.8% were Saudis. They had a mean
age of 37.36 years (range 21–70 years), and their mean dis-
ease duration was 5.4 years (range 1–24 years); 22% of thepatients enrolled suﬀered of psoriatic arthritis (PsA), and
80% had a body mass index (BMI) of more than 25.
At baseline, the enrolled patients had a mean PASI
score of 15.17 points, and a mean Zung depression score
of 60.84 points (range 50–76). 46.7%, 33.3% and 20% of
patients suﬀered of mild, moderate and severe depression
respectively.
After baseline assessment and collecting consent all
patients were screened for tuberculosis and infection then
administered a loading dose of adalimumab (80 mg subcu-
taneously); 64.4% of patients were on concomitant medica-
tions at the time of ﬁrst administration of adalimumab,
more details about concomitant medications are present
in Table 1.
At month 6 after starting adalimumab, Mean PASI
score of enrolled patients was signiﬁcantly reduced from
15.17 at baseline to 3.32 at month 6 (p < 0.0001), and the
mean Zung depression score was signiﬁcantly reduced from
60.84 to 35.29 (p < 0.0001) (Figure 1). 80% of enrolled
patients achieved P75% improvement in their PASI score
(PASI75) at month 6 of adalimumab therapy and 97.8%
achieved a meaningful improvement of the Zung depres-
sion score (more than 6 points decline in the Zung depres-
sion score). At the end of the study, 9% of enrolled patients
had mild depression, while 92% showed no depression
(Zung score < 49 points).
Compliance rate for adalimumab therapy was 87.8%,
measured by comparing the number of doses planned for
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doses actually administered during the same period. There
was no withdrawal from the study at the end of 6 months.
One patient suﬀered from gastrointestinal disorders
while another patient developed respiratory tract infection
during the duration of the study; both were managed and
continued their treatment regimen.
Regression analyses were conducted to determine pre-
dictors of depression in the patients enrolled in the study.
Age at the time of assessment signiﬁcantly predicted
depression (p = 0030), with the younger age predicting a
higher depression score (standard co-eﬃcient .451).
Achieving PASI 75 could signiﬁcantly predict improvement
in depression (p = 0.002, standard co-eﬃcient .746). Gen-
der, race, BMI, disease duration and the presence of psori-
atic arthritis all could not signiﬁcantly predict depression
severity. Our study did not show signiﬁcant diﬀerence in
results between patients with concomitant medications
and those without concomitant medications.
6. Discussion
The eﬀective treatment of psoriasis has been found to
improve symptoms of depression associated with the con-
dition (Fortune et al., 2004).
Our patients were assessed for depression symptoms
using the Zung Self-rating Depression Scale (ZDS). It has
the advantage of acceptable reliability and being available
in the public domain. It was developed as a short, simple
and quantitative self-report measure of depression. The
scale attempts to include all of the symptoms of depression.
The items aim to penetrate the aﬀective, behavioral, cogni-
tive and physiological aspects of depression. The items
were selected on the basis of the diagnostic criteria for
depression and factor analytic studies.
Our study incorporated classic depression assessment
instruments to examine an important question: does a
known eﬀective treatment for the clinical symptoms of pla-
que psoriasis improve symptoms of psoriasis-associated
depression, which are conjectured to involve a cytokine
that is closely involved in the disease process of psoriasis?
We found that symptoms of depression were signiﬁcantly
improved with adalimumab. Related ﬁndings have been
previously reported with adalimumab (Menter, 2010) and
etanercept (Tyring et al., 2006) suggesting that anti-TNFa
therapies such as a class can reduce depression in patients
with psoriasis.
During the 24-week treatment period, however, reduc-
tions in depression symptoms were signiﬁcantly correlated
with reductions in psoriasis severity.
PASI 75 responders experienced a signiﬁcantly greater
improvement in depression symptoms than non
responders.
This result is consistent with that of Mentor et al.
Menter (2010), but inconsistent with the results of Tyring
et al. (2006) who failed to detect strong correlation between
PASI and depression improvement.During the last 10 years, it has been established that
pro-inﬂammatory cytokines such as interleukin-1 (IL-1),
IL-6 and TNF-a induce true major depressive disorders
in physically ill patients with no previous history of
mental disorders (Dantzer et al., 2008). For example,
TNF-a has been found to increase in depressed female
patients when compared with healthy women (Kahl
et al., 2006). And it was hypothesized that these immune
alterations associated with depression may contribute to
the pathophysiologic processes of the associated disorders
e.g. osteoporosis, dyslipidemia and diabetes and psoriasis
(Kahl et al., 2005).
Three diﬀerent mechanisms might link the activation of
the cytokine system, of which TNF-a is a part, to the path-
ophysiology of depression. At ﬁrst, as proinﬂammatory
cytokines and serotonergic homeostasis have both been
implicated in the pathophysiology of major psychiatric dis-
orders, various authors hypothesized that cytokines might
also activate neuronal serotonin transporter. This idea
would underline the theory of a serotonin deﬁciency during
depression and the pharmacodynamic mechanism of selec-
tive serotonin reuptake inhibitors (SSRI) in the treatment
of depression, because SSRIs lead to recovery from depres-
sion via deactivation of serotonin transporters (Pickering
et al., 2005). Zhu et al. found TNF-a stimulated serotonin
uptake in both a rat embryonic raphe cell line and in mouse
midbrain and striatal synaptosomes. These results provided
evidence that proinﬂammatory cytokines can acutely regu-
late neuronal serotonin transporter activity (Zhu et al.,
2006).
Second, immune activation with increased production of
pro-inﬂammatory cytokines activates the tryptophan- and
serotonin-degrading enzyme indolamine-2,3-dioxygenase
(IDO) Wichers and Maes, 2002.
Third, it has been postulated that the activation of the
cytokine system might play a causative role in the depres-
sion related activation of the hypothalamic pituitary axis
system (O’Brien et al., 2004; Scho¨bitz et al., 1994;
Silverman et al., 2005).
However, the role of the soluble TNF-a receptors p55
and p75 (sTNF-R p55 and p75) has not been investigated
so far in patients with depressive disorder. One single study
in patients with heart failure found elevated sTNF-R p55
levels associated with a higher risk for depression
(Moorman et al., 2007).
Langley et al., observed signiﬁcant improvement in anx-
iety and depression scores in patients treated with ustekinu-
mab, with signiﬁcant correlation between improvement in
PASI score and improvement in anxiety and depression
score (Langley et al., 2010).
These ﬁndings suggest that inhibition of inﬂammatory
cytokines in patients with depression may improve depres-
sion symptoms, but further studies are needed to address
this question. Although psoriasis is an inﬂammatory dis-
ease mediated by TNF, it is unclear to what degree depres-
sion in psoriasis is TNF mediated versus a consequence of
other psoriasis symptoms. The results of this analysis
A. Elgendi et al. / Journal of Dermatology & Dermatologic Surgery 19 (2015) 15–20 19cannot distinguish whether adalimumab has a direct or
indirect eﬀect on depression.
Alternatively, the presence of a strong correlation
between PASI and depression improvement after treatment
with both adalimumab and ustekinumab could indicate
that treatment aﬀected severity of depression indirectly.
However, the study was not designed to detect any eﬀect
of treatment with adalimumab on primary depression.
The psychological eﬀects of psoriasis are not strictly
determined by the severity of skin manifestations: environ-
mental, cognitive, and life-event factors might all interact
to perpetuate depression despite improvements in skin
disease.
The fairly short treatment period during which depres-
sion data were collected (24 weeks) may have limited our
ﬁndings; therefore, additional long-term studies would be
useful in further elucidating the long-term impact of ada-
limumab on anxiety and depression in patients with mod-
erate-to-severe psoriasis.
A broader concept of depression in the context of psori-
asis will permit consideration of the usefulness of pharma-
cological and biopsychosocial approaches in the
management of this complex condition. Thus, this study
represents an important advancement in knowledge about
psoriasis and the symptoms of depression, and the relation
between them.
7. Conclusion
Adalimumab relieves symptoms of depression in
patients with moderate to severe psoriasis. There was a sig-
niﬁcant correlation between reduction in depression symp-
toms and the improvement in psoriasis severity, age at the
onset of disease was the only other factor that is correlated
with improvement in depression. The high prevalence of
depression among patients included in this study suggests
that screening for depression symptoms should be incorpo-
rated into dermatology practice as a part of the manage-
ment of psoriasis.
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